Raja Iqbal Mulya Harahap, Juandika Juandika, Dety Mulyanti
{"title":"PERBANDINGAN BIAYA PEMERIKSAAN LABORATORIUM PADA PASIEN TUBERKULOSIS MULTIDRUG RESISTANCE (TB-MDR) DENGAN TUBERKULOSIS EXTENSIVE DRUG RESISTANCE (TB-XDR): STUDI PADA RUMAH SAKIT TERSIER DI BANDUNG","authors":"Raja Iqbal Mulya Harahap, Juandika Juandika, Dety Mulyanti","doi":"10.59581/diagnosa-widyakarya.v1i1.156","DOIUrl":null,"url":null,"abstract":"Introduction. Tuberculosis (TB) is one of the oldest diseases known to attack humans, caused by the bacterium Mycobacterium tuberculosis. Multi-drug-resistant TB (MDR-TB) is a stage or condition in which Mycobacterium tuberculosis becomes minimally resistant to rifampicin administration and also insonicotinylhydrazine (INH). Extensive-drug-resistant TB (XDR-TB) is an MDR-TB with Mycobacterium tuberculosis immune characteristics against one of the fluoroquinolone class drugs and one of the second-line injection OAT (capreomycin, kanamycin, and amikacin). The aim of this study was to find out the description of variation in laboratory costs of MDR-TB/XDR patients on one treatment cycle. \nMethod. The inclusion criteria were patients who had been diagnosed with MDR-TB/XDR and performed laboratory tests. The design of this study was a cross-sectional retrospective analytics using medical records of MDR-TB/XDR patients in MDR division. \nResults. There were 30 MDR-TB research subjects and 2 XDR-TB research subjects examined for laboratory examination. Comparison of laboratory mean of MDR-TB/XDR (p = 0,018). \nDiscussion. There was a significant difference in the total cost of MDR-TB/XDR laboratory examinations in one treatment cycle. \nConclusion. Laboratory examination of MDR-TB/XDR patients requires considerable cost, this is due to the side effects of OAT that require patient clinical monitoring. \n \n ","PeriodicalId":204202,"journal":{"name":"DIAGNOSA: Jurnal Ilmu Kesehatan dan Keperawatan","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DIAGNOSA: Jurnal Ilmu Kesehatan dan Keperawatan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59581/diagnosa-widyakarya.v1i1.156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
PERBANDINGAN BIAYA PEMERIKSAAN LABORATORIUM PADA PASIEN TUBERKULOSIS MULTIDRUG RESISTANCE (TB-MDR) DENGAN TUBERKULOSIS EXTENSIVE DRUG RESISTANCE (TB-XDR): STUDI PADA RUMAH SAKIT TERSIER DI BANDUNG
Introduction. Tuberculosis (TB) is one of the oldest diseases known to attack humans, caused by the bacterium Mycobacterium tuberculosis. Multi-drug-resistant TB (MDR-TB) is a stage or condition in which Mycobacterium tuberculosis becomes minimally resistant to rifampicin administration and also insonicotinylhydrazine (INH). Extensive-drug-resistant TB (XDR-TB) is an MDR-TB with Mycobacterium tuberculosis immune characteristics against one of the fluoroquinolone class drugs and one of the second-line injection OAT (capreomycin, kanamycin, and amikacin). The aim of this study was to find out the description of variation in laboratory costs of MDR-TB/XDR patients on one treatment cycle.
Method. The inclusion criteria were patients who had been diagnosed with MDR-TB/XDR and performed laboratory tests. The design of this study was a cross-sectional retrospective analytics using medical records of MDR-TB/XDR patients in MDR division.
Results. There were 30 MDR-TB research subjects and 2 XDR-TB research subjects examined for laboratory examination. Comparison of laboratory mean of MDR-TB/XDR (p = 0,018).
Discussion. There was a significant difference in the total cost of MDR-TB/XDR laboratory examinations in one treatment cycle.
Conclusion. Laboratory examination of MDR-TB/XDR patients requires considerable cost, this is due to the side effects of OAT that require patient clinical monitoring.